For a clinical trial exploring hydroxychloroquine as preventive treatment for COVID-19Rising Pharma Holdings Inc., the global pharmaceutical company operating as Rising Pharmaceuticals announced its collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease on a clinical trial exploring hydroxychloroquine as preventive treatment for coronavirus disease 2019 (COVID-19).
Hydroxychloroquine is a medication used for the prevention and treatment of certain types of malaria, as well as rheumatoid arthritis, lupus, and porphyria cutanea tarda.
The trial is being led by internationally recognized infectious disease expert David Boulware, MD, MPH and his research team among 1,500 healthcare workers or household contacts exposed to COVID-19. In non-human studies, researchers have identified two medicines, chloroquine and hydroxychloroquine, as having activity against SARS-coronaviruses.
Rising Pharmaceuticals -- and its partner Laurus Labs in Hyderabad, India -- manufacture Hydroxychloroquine Sulphate, USP Tablets under an FDA approved drug application. Rising Pharmaceuticals is the exclusive distributor of the product in the United States.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)